Minerva Neurosciences, Inc. (NERV) Insider Trading Activity

NASDAQ$4.63
Market Cap
$32.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
691 of 870
Rank in Industry
399 of 505

NERV Insider Trading Activity

NERV Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Insider Activity of Minerva Neurosciences, Inc.

Over the last 12 months, insiders at Minerva Neurosciences, Inc. have bought $0 and sold $0 worth of Minerva Neurosciences, Inc. stock.

On average, over the past 5 years, insiders at Minerva Neurosciences, Inc. have bought $0 and sold $127,576 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,000 shares for transaction amount of $20,790 was made by VAN HEEK G JAN (director) on 2020‑09‑10.

List of Insider Buy and Sell Transactions, Minerva Neurosciences, Inc.

2023-05-02SaleLuthringer RemyCEO
3,641
0.0559%
$3.76
$13,690
+44.12%
2023-05-01SaleLuthringer RemyCEO
23,753
0.4554%
$3.85
$91,449
+75.93%
2023-05-01SaleRace GeoffPresident
22,082
0.4234%
$3.85
$85,016
+75.93%
2023-05-01SaleAhlholm Frederick WSVP, CFO and Secretary
3,580
0.0799%
$4.48
$16,038
+75.93%
2021-12-01SaleKupfer Daviddirector
55,635
0.1267%
$0.88
$48,959
-24.72%
2020-12-16SaleRace GeoffEVP, CFO & CBO
6,190
0.0149%
$2.64
$16,342
-10.31%
2020-12-16SaleLuthringer RemyCEO
1,300
0.0031%
$2.64
$3,432
-10.31%
2020-12-16SaleReilly Joseph H.SVP & Chief Operating Officer
3,228
0.0078%
$2.64
$8,522
-10.31%
2020-12-16SaleAhlholm Frederick WSVP, Chief Accounting Officer
1,845
0.0044%
$2.64
$4,871
-10.31%
2020-09-10PurchaseVAN HEEK G JANdirector
7,000
0.0171%
$2.97
$20,790
-0.86%
2020-05-26SaleAhlholm Frederick WSVP, Chief Accounting Officer
8,339
0.0216%
$15.00
$125,085
-78.03%
2019-12-17SaleRace GeoffEVP, CFO & CBO
5,826
0.0152%
$7.10
$41,365
-46.98%
2019-12-17SaleLuthringer RemyCEO
2,412
0.0063%
$7.10
$17,125
-46.98%
2019-12-17SaleReilly Joseph H.SVP & Chief Operating Officer
2,724
0.0071%
$7.10
$19,340
-46.98%
2019-12-17SaleAhlholm Frederick WSVP, Chief Accounting Officer
1,557
0.0041%
$7.10
$11,055
-46.98%
2019-12-12SaleRussell Richard E.President
3,113
0.0078%
$7.42
$23,098
-50.13%
2019-06-27PurchaseDOYLE WILLIAM Fdirector
3,500
0.009%
$5.50
$19,250
+23.53%
2019-06-26PurchaseKupfer Daviddirector
10,000
0.0264%
$5.55
$55,500
+25.05%
2019-06-26PurchaseVAN HEEK G JANdirector
10,000
0.0255%
$5.37
$53,700
+25.05%
2019-06-26PurchaseHASLER HANS PETERdirector
10,000
0.0266%
$5.60
$56,000
+25.05%
Total: 98

Insider Historical Profitability

<0.0001%
Ollier Michele
4488272
64.1826%
$20.78M21
<0.0001%
De Rubertis Francesco
4488272
64.1826%
$20.78M21
<0.0001%
Index Venture Associates III Ltd10 percent owner
3899189
55.7587%
$18.05M218
<0.0001%
JOHNSON & JOHNSON10 percent owner
3892256
55.6596%
$18.02M20
<0.0001%
Pellegrini Lorenzo
3883212
55.5302%
$17.98M10
<0.0001%
Care Capital III LLC10 percent owner
1662592
23.7752%
$7.7M17
<0.0001%
Kupfer Daviddirector
163553
2.3388%
$757,250.3941
<0.0001%
Luthringer RemyCEO
68994
0.9866%
$319,442.2208
Race GeoffPresident
51324
0.7339%
$237,630.1217
<0.0001%
Beer Marc Ddirector
50000
0.715%
$231,500.0020
<0.0001%
Vivaldi Coelho RogerioPresident and CEO
41667
0.5958%
$192,918.2110
<0.0001%
Russell Richard E.President
33770
0.4829%
$156,355.1002
Reilly Joseph H.SVP & Chief Operating Officer
31747
0.454%
$146,988.6117
<0.0001%
DOYLE WILLIAM Fdirector
26111
0.3734%
$120,893.93110
<0.0001%
VAN HEEK G JANdirector
20333
0.2908%
$94,141.7930
<0.0001%
Ahlholm Frederick WSVP, CFO and Secretary
17518
0.2505%
$81,108.3418
<0.0001%
HASLER HANS PETERdirector
10000
0.143%
$46,300.0010
HILLEMAN JERYL Ldirector
1000
0.0143%
$4,630.0010
Levine Mark S.SVP,General Counsel & Sec.
0
0%
$002

Historical Insider Profitability vs. Competitors

$18,815,063
62
-6.39%
$20.77M
$6,204,522
45
1.91%
$25.55M
Minerva Neurosciences, Inc.
(NERV)
$95,303,339
30
-13.78%
$32.38M
$2,983,776
25
-16.47%
$32.97M
$523,320
24
94.37%
$34.12M
$241,165
22
-16.72%
$33.26M
$351,813
19
21.51%
$32.97M
$3,556,951
18
9.64%
$38.87M
$13,486,672
11
82.26%
$29.7M
$189,648
9
-52.20%
$32.5M
$654,995
7
-60.00%
$27.32M
$8,470,804
6
-13.28%
$19.53M
$104,699
5
-12.61%
$39.18M
$26,254,149
5
49.97%
$30.69M
$657,791
4
-52.05%
$35.22M
$100,266
2
3.17%
$25.47M
$16,526,031
2
-0.85%
$27.06M
$4,030
1
9.14%
$42.91M
$30,190
1
-42.39%
$31.69M

NERV Institutional Investors: Active Positions

Increased Positions22+88%21M+1,067.25%
Decreased Positions9-36%36,318-1.83%
New Positions14New17MNew
Sold Out Positions5Sold Out22,745Sold Out
Total Postitions38+52%23M+1,065.42%

NERV Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Federated Hermes, Inc.$5,297.003.14%1.35M00%2025-09-30
Vanguard Group Inc$988.000.59%252,029-31-0.01%2025-09-30
Renaissance Technologies Llc$457.000.27%116,500+5,500+4.96%2025-09-30
Geode Capital Management, Llc$296.000.18%75,62500%2025-09-30
Blackrock, Inc.$285.000.17%72,66900%2025-09-30
Apella Capital, Llc$154.000.09%39,314+18,375+87.75%2025-09-30
Acadian Asset Management Llc$68.000.04%17,41600%2025-09-30
State Street Corp$65.000.04%16,51900%2025-09-30
Adar1 Capital Management, Llc$49.000.03%12,40600%2025-09-30
Morgan Stanley$43.000.03%11,00800%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.